By Professor Paul De Souza

Journal articles

McPherson RAC; Galettis PT; De Souza PL, 2009, 'Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells', British Journal of Cancer, 100, pp. 649 - 655, http://dx.doi.org/10.1038/sj.bjc.6604920

Figlin R; De Souza PL; McDermott D; Dutcher J; Berkenblit A; Thiele A; Krygowski M; Strahs A; Feingold J; Boni J; Hudes G, 2009, 'Analysis of PTEN and HIF-1 alpha and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-alpha', Cancer, 115, pp. 3651 - 3660

Crombie C; Burns W; Karapetis C; Lowenthal RM; Kirsten F; Davidson J; Abell F; Reece W; Iglesias J; De Souza PL, 2009, 'Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non-small-cell lung cancer: Is thrombocytopenia predictable?', Asia-Pacific Journal of Clinical Oncology, 5, pp. 24 - 31

Amaral MB; Buchholz I; Freire-Maia B; Reher P; De Souza PEA; De Marigo HA; Martins CR; Horta MCR, 2008, 'Advanced osteosarcoma of the maxilla: A case report', Medicina Oral, Patologia Oral y Cirugia Bucal, 13

Goldstein D; Bennett B; Cameron B; Boyle F; DeSouza P; Wilcken N; Friedlander M; Scott E; Hickie I; Lloyd AAM, 2008, 'A prospective cohort study of fatigue after adjuvant therapy for breast cancer: Association with hematologic, endocrine, and immune parameters', JOURNAL OF CLINICAL ONCOLOGY, 26, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.9596

Hutson TE; Davis ID; Machiels JH; de Souza PL; Baker K; Bordogna W; Westlund R; Crofts T; Pandite L; Figlin RA, 2008, 'Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor', JOURNAL OF CLINICAL ONCOLOGY, 26, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.5046

de Souza PL; Radulovic S; Beck J; Pendergrass K; Siddique N; Dutcher JP; Berkenblit A; Thiele A; Krygowski M; Hudes GR, 2008, 'Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α', Journal of Clinical Oncology, 26, pp. 5116 - 5116, http://dx.doi.org/10.1200/jco.2008.26.15_suppl.5116

Hutson TE; Davis ID; Machiels JP; de Souza PL; Hong BF; Rottey S; Baker KL; Crofts T; Pandite L; Figlin R, 2007, 'Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)', Journal of Clinical Oncology, 25, pp. 5031 - 5031, http://dx.doi.org/10.1200/jco.2007.25.18_suppl.5031

de Souza P; Maart K; Laurell A; Hawkins RE; Berkenblit A; Galand L; Thiele A; Strahs A; Feingold J; Hudes G, 2007, '4011 POSTER Results of a phase 3, randomized study of patients with advanced renal cell carcinoma (RCC) and poor prognostic features treated with temsirolimus, interferon-a or the combination of temsirolimus + interferon-a', European Journal of Cancer Supplements, 5, pp. 282 - 283, http://dx.doi.org/10.1016/s1359-6349(07)71079-0

Friedlander ML; Buck MD; Wyld D; Findlay M; Fitzharris B; De Souza PL; Davies TM; Kalimi G; Allan S; Perez DM; Harnett PH, 2007, 'Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer', International Journal of Gynecological Cancer, 17, pp. 350 - 358

Harnett PH; Buck MD; Beale P; Goldrick AJ; Allan S; Fitzharris B; De Souza PL; Links MR; Kalimi G; Davies TM; Stuart-Harris R, 2007, 'Phase II study of gemcitabine and oxaliplatin in patients with recurrent ovarian cancer: an Australian and New Zealand Gynaecological Oncology Group study', International Journal of Gynecological Cancer, 17, pp. 359 - 366

Grimison PS; Galettis P; Metharom E; De Souza PL; Links MJ; Liauw WS; Manners S; Jelinek M, 2007, 'Randomized crossover study evaluating the effect of gemcitabine infusion dose rate : evidence of auto-induction of gemcitabine accumulation', Journal of Clinical Oncology, 25, pp. 5704 - 5709

Gan HK; Mitchell P; Galettis P; Davis I; Cebon J; De Souza PL; Links MJ, 2006, 'A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors', Cancer Chemotherapy and Pharmacology, 58, pp. 157 - 164

Graham PH; Clark C; Abell F; Browne L; Capp A; Clingan PR; De Souza PL; Fox C; Links MJ, 2006, 'Concurrent-phase boost high-dose radiation therapy for non-small-cell lung cancer with or without cisplatin chemotherapy', Journal of Medical Imaging and Radiation Oncology, 50, pp. 342 - 348

De Souza PL; Liauw WS; Links MJ; Pirabhahar S; Kelly G; Lowes LG, 2006, 'Phase I and pharmacokinetic study of weekly NV06 (Phenoxodioltrade mark), a novel isoflav-3-ene, in patients with advanced cancer', Cancer Chemotherapy and Pharmacology, 58, pp. 427 - 433

Rosen L; Gordon D; Tchekmedyian N; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza PL; Zheng M; Urbanowitz G; Reitsma D; Seaman J, 2004, 'Long-term efficacy and safety of zoledronic acid in the treatment ofskeletal metastases in patients with nonsmall cell lung carcinoma andother solid tumors - A randomized, phase III, double-blind,placebo-controlled trial', Cancer, 100, pp. 2613 - 2621

Rosen LS; Gordon D; Tchekmedyian S; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; de Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman JJ, 2003, 'Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group', Journal of Clinical Oncology, 21, pp. 3150 - 3157, http://dx.doi.org/10.1200/JCO.2003.04.105

Souquet PJ; Price A; Jaworski M; Burillon JP; Aubert D; Fernandez O; Lewis C; De Souza P; Bosque L; Rodrigues Pereira J; Kolec V; Marel M; Astoul P; Jounieaux A; Riou R; Tack V; Deppermann KM; Gatzmeier U; Koschel G; Kreuser ED; Schlimok G; Von Pawel J; Isokangas OP; Mattson K; Torrecillas L; Lira Puerto V; Barroso N; Van Klaveren R; Gallardo D; Utraka B; Barnardt P; Tan EH; Sevilla Garcia I; Moreno Nogueira JA; Betticher D; Stahel R; Wernli M; Shih JF; Clark P; Harper P; Price A, 2003, 'Erratum: GLOB-1: A prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients (Annals of Oncology) (2002) vol. 13 (1853-1861))', Annals of Oncology, 14, pp. 347, http://dx.doi.org/10.1093/annonc/mdg083

Liauw W; Links M; Pirabhahar S; Husband A; Kelly G; De Souza PL, 2001, 'Phase I trial of weekly NV-06 (Phenoxodiol (TM)), a novel isoflavonoid, in patients with advanced cancer.', CLINICAL CANCER RESEARCH, 7, pp. 3694S - 3694S, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000172121800205&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Diamond TH; Winters J; Smith A; De Souza P; Kersley JH; Lynch WJ; Bryant C, 2001, 'The anti osteo porotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade - A double blind, randomized, placebo-controlled crossover study', CANCER, 92, pp. 1444 - 1450, http://dx.doi.org/10.1002/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M

Diamond TH; Winters J; Smith A; De Souza P; Kersley JH; Lynch WJ; Bryant C, 2001, 'The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: A double blind, randomized, placebo-controlled crossover study', Cancer, 92, pp. 1444 - 1450, http://dx.doi.org/10.1002/1097-0142(20010915)92:6<1444::AID-CNCR1468>3.0.CO;2-M

Cohen RM; Mueller SC; Haden K; De Souza PL, 2000, 'Phase I study of weekly vinorelbine in combination with weekly paclitaxel in adult patients with advanced refractory cancer', Cancer Investigation, 18, pp. 422 - 428

De Souza PL; Cooper MR; Imondi AR; Myers CE, 1997, '9-Aminocamptothecin: A topoisomerase I inhibitor with preclinical activity in prostate cancer', Clinical Cancer Research, 3, pp. 287 - 294

De Souza PL; Castillo M; Myers CE, 1997, 'Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine', British Journal of Cancer, 75, pp. 1593 - 1600, http://dx.doi.org/10.1038/bjc.1997.272

Stea S; Bachelor T; Cooper M; De Souza P; Koenig K; Bolton WK, 1996, 'Disposition and bioavailability of ceftazidime after intraperitoneal administration in patients receiving continuous ambulatory peritoneal dialysis', Journal of the American Society of Nephrology, 7, pp. 2399 - 2402

De Souza PL; Friedlander ML, 1995, 'Humoral hypercalcemia associated with adenocarcinoma of the rectum: A case report and review of the literature', American Journal of Clinical Oncology: Cancer Clinical Trials, 18, pp. 126 - 129, http://dx.doi.org/10.1097/00000421-199504000-00006

De Souza P; Friedlander M; Wilde C; Kirsten F; Ryan M, 1994, 'Hypersensitivity reactions to etoposide: A report of three cases and review of the literature', American Journal of Clinical Oncology: Cancer Clinical Trials, 17, pp. 387 - 389, http://dx.doi.org/10.1097/00000421-199410000-00005

de Souza P, 1993, 'Medical management of miscarriage with RU486.', Med J Aust, 159, pp. 491, https://www.ncbi.nlm.nih.gov/pubmed/8292160

De Souza P; Smith RD; Hall J; Gurney H; Harnett PR, 1993, 'A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma [5]', Medical Journal of Australia, 158, pp. 866, http://dx.doi.org/10.5694/j.1326-5377.1993.tb137685.x

De Souza PL; Friedlander ML, 1992, 'Prognostic factors in ovarian cancer', Hematology/Oncology Clinics of North America, 6, pp. 761 - 781, http://dx.doi.org/10.1016/s0889-8588(18)30309-5

Friedlander M; De Souza P; Segelov E, 1992, 'Risk factors, epidemiology, screening, and prognostic factors in female genital cancer', Current Opinion in Oncology, 4, pp. 913 - 922, http://dx.doi.org/10.1097/00001622-199210000-00016

Conference Papers

Lee DH; Roohullah A; Cho BC; Lemech CR; De Souza PL; Millward M; Choi JY; Park KE; Kim NY; Kim E; Lee S; Kim Y; Shin Y; Han J-Y, 2022, 'A phase 1 dose-escalation study of the ABN401 (c-MET inhibitor) in patients with solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680300998&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Gu S; de Souza PL; Shi Y; Han W; Luo S; Chen J; Day D; Frentzas S; Park JJ; Shao G; Wu S; Fang M; Haydon AM; Sun S; Lei K; Ding L; Zuo R; Gan X; Zhao Y; Chen X, 2022, 'A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680300865&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Richardson GE; Tolcher AW; Morris MF; De Souza PL; Hamid A; She X; Zhu L; Wang H; Zheng S; Liu G; Li Y; Du FF; Fischkoff S; Gong H; Zha J; Luo P, 2022, 'Phase 1 study of ADG126, a novel masked anti-CTLA-4 SAFEbody, that combines tumor-localized activation with strong T-reg depletion and soft ligand blocking in patients with advanced solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, pp. E17601 - E17601, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 03 June 2022 - 07 June 2022, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000863680303552&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

de Souza P; Park J; Day D; Frentzas S; Haydon AM; Ji J; de Assis MM; Chen X; Gan X; Tao X; Zuo R; Ross G; Lu L, 2021, 'A phase I dose-escalation study of HBM4003: An anti-CTLA-4 heavy-chain-only mAb', in ANNALS OF ONCOLOGY, ELSEVIER, ELECTR NETWORK, pp. S855 - S855, presented at Congress of the European-Society-for-Medical-Oncology (ESMO), ELECTR NETWORK, 16 September 2021 - 21 September 2021, http://dx.doi.org/10.1016/j.annonc.2021.08.1399

Shah MM; Bodocian H; Zauner R; Sajinovic M; De Souza P; Wally V; Mellick AS, 2020, 'MIR-10B AS A MARKER FOR DISSEMINATED DISEASE IN RDEB-LINKED SCCS', in ACTA DERMATO-VENEREOLOGICA, ACTA DERMATO-VENEREOLOGICA, pp. 60 - 61, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000568327600162&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Wimmer M; Zauner R; Ablinger M; Pinon-Hofbauer J; Guttmann-Gruber C; Reisenberger M; Lettner T; Niklas N; Proell J; Sajinovic M; De Souza P; Hainzl S; Murauer EM; Bauer JW; Strunk D; Reichelt J; Mellick AS; Wally V, 2020, 'MIRNA-10B MARKS AGGRESSIVE SQUAMOUS CELL CARCINOMAS IN RDEB', in ACTA DERMATO-VENEREOLOGICA, ACTA DERMATO-VENEREOLOGICA, pp. 35 - 36, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000568327600097&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Kotasek D; Coward J; de Souza PL; Underhill C; Jin X; Li B; Xia Y; Prawira A, 2019, 'A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.e14006

Ding PN; Becker T; Bray VJ; Chua W; Ma YF; Luk A; Po J; Lynch D; Caixeiro N; de Souza P; Roberts TL, 2018, 'Longitudinal analysis of circulating biomarkers to monitor advanced EGFR mutated (EGFR+) non-small cell lung cancer (NSCLC)', in Annals of oncology : official journal of the European Society for Medical Oncology, pp. viii660, http://dx.doi.org/10.1093/annonc/mdy303.033

Bang Y-J; De Souza P; Kim S-W; Lickliter J; Naito Y; Park K; Kumar S; Mugundu GM; Kato H, 2018, 'Abstract B183: The WEE1 inhibitor AZD1775 in combination with chemotherapy in Asian patients with advanced solid tumors: a phase Ib study', in Molecular Cancer Therapeutics, American Association for Cancer Research (AACR), pp. B183 - B183, http://dx.doi.org/10.1158/1535-7163.targ-17-b183

Bergin ART; Hovey E; Lloyd A; Marx G; Parente P; Rapke T; de Souza P, 2017, 'Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis', in Supportive Care in Cancer, pp. 2871 - 2879, http://dx.doi.org/10.1007/s00520-017-3706-8

Lim SH-S; Ip E; Chua W; Ng W; Henderson C; Shin J-S; Harris BHL; Barberis A; Cowley M; De Souza PL; Spring K, 2017, 'Serum microRNA expression during neoadjuvant chemoradiation for rectal cancer.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at 53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2017 - 06 June 2017, http://dx.doi.org/10.1200/JCO.2017.35.15_suppl.e15081

Zamboni WC; Markman B; de Souza P; Dees EC; Gangadhar T; Eliasof S; Murphy C; Senderowicz A; Wang H, 2016, 'Abstract 2047: Pharmacokinetics (PK) of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing the payload docetaxel, in patients with refractory solid tumors', in Cancer Research, American Association for Cancer Research (AACR), pp. 2047 - 2047, http://dx.doi.org/10.1158/1538-7445.am2016-2047

Markman B; De Souza PL; Dees EC; Gangadhar TC; Cooper A; Roohullah A; Boolell V; Zamboni W; Murphy C; Senderowicz AM; Wang H, 2016, 'A phase 1 study of CRLX301, a novel nanoparticle-drug conjugate (NDC) containing docetaxel (DOC), in patients with refractory solid tumors.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 03 June 2016 - 07 June 2016, http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.2526

Lim SH; De Souza P; Chua W; Ng W; Harris B; Cowley MJ; Spring K, 2016, 'Change in serum microRNA expression during neoadjuvant chemoradiation for rectal cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, LA, New Orleans, presented at 107th Annual Meeting of the American-Association-of-Cancer-Research (AACR), LA, New Orleans, 16 April 2016 - 20 April 2016, http://dx.doi.org/10.1158/1538-7445.AM2016-1942

Spring K; Lim S; Descallar J; Ng W; Chua W; de Souza P; Bokey L; MacKenzie S, 2015, 'Circulating tumour cell release in the peri-operative setting during curative colorectal cancer surgery', in Annals of Oncology, Oxford University Press (OUP), Barcelona, SPAIN, presented at ESMO 17th World Congress on Gastrointestinal Cancer, Barcelona, SPAIN, 01 July 2015 - 04 July 2015, http://dx.doi.org/10.1093/annonc/mdv233.297

Ryan CJ; Smith MR; Fizazi K; Saad F; Sternberg CN; Logothetis C; Small EJ; Carles J; Flaig TW; Taplin M-E; Higano CS; De Souza PL; De Bono JS; Griffin TW; De Porre P; Park YC; Li J; Kheoh TS; Molina A; Rathkopf DE, 2015, 'Impact of crossover and baseline prognostic factors on overall survival (OS) with abiraterone acetate (AA) in the COU-AA-302 final analysis.', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, FL, Orlando, presented at Genitourinary Cancers Symposium, FL, Orlando, 26 February 2015 - 28 February 2015, http://dx.doi.org/10.1200/jco.2015.33.7_suppl.142

Lim SH-S; Shin J-S; Tut TG; Ng WTW; Chug W; Dissanayake IU; Spring K; Ng W; Bokey L; De Souza P; Lee CS, 2014, 'Polo-like kinase 1 as a biomarker in rectal cancers', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at 50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 30 May 2014 - 03 June 2014, http://dx.doi.org/10.1200/jco.2014.32.15_suppl.e14542

Yu EY; Saad F; Londhe A; Shore ND; Van Poppel H; Rathkopf DE; Smith MR; Logothetis C; De Souza PL; Fizazi K; Mulders PFA; Mainwaring PN; Hainsworth JD; Beer TM; North SA; Small EJ; Scher HI; Griffin TW; Yu MK; Ryan CJ, 2014, 'Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium, CA, San Francisco, 30 January 2014 - 01 February 2014, http://dx.doi.org/10.1200/jco.2014.32.4_suppl.27

Sardjono C; Bower J; McCloud P; Mainwaring P; Sewak S; Wong S; Kotasek D; Lee SH; Chung JS; Sanmugarajah J; Troon S; Yip D; Singh N; Crump D; de Souza P, 2014, 'A PHASE II STUDY OF SEQUENTIAL THERAPY WITH PAZOPANIB FOLLOWED BY EVEROLIMUS IN METASTATIC RENAL CELL CANCER - STUDY UPDATE', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 65 - 65, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339716500059&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page